Compare ANIK & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | NUS |
|---|---|---|
| Founded | 1983 | 1984 |
| Country | United States | United States |
| Employees | N/A | 8600 |
| Industry | Medical/Dental Instruments | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 236.1M |
| IPO Year | 1996 | 1996 |
| Metric | ANIK | NUS |
|---|---|---|
| Price | $20.86 | $4.85 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 95.8K | ★ 468.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | 80.16 | ★ 207.80 |
| EPS | ★ N/A | N/A |
| Revenue | $112,819,000.00 | ★ $3,176,718,000.00 |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $7.42 | $7.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.98 |
| 52 Week Low | $8.56 | $4.49 |
| 52 Week High | $22.88 | $14.62 |
| Indicator | ANIK | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 48.02 |
| Support Level | $20.13 | $4.52 |
| Resistance Level | $22.70 | $4.95 |
| Average True Range (ATR) | 0.86 | 0.18 |
| MACD | -0.25 | 0.03 |
| Stochastic Oscillator | 28.81 | 67.09 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.